Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
about
Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, MozambiqueArtemisinin-based combination therapy for uncomplicated P. falciparum malaria in children with HIVPotencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malariaPlasmepsin V licenses Plasmodium proteins for export into the host erythrocyteArtemisinin-based combination therapy for uncomplicatedP. falciparummalaria in children with HIVHIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensisNeither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primatesEctopic expression of a Neospora caninum Kazal type inhibitor triggers developmental defects in Toxoplasma and PlasmodiumHIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitroHIV treatments reduce malaria liver stage burden in a non-human primate model of malaria infection at clinically relevant concentrations in vivoExpanding the Antimalarial Drug Arsenal-Now, But How?A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype-dependent variations in drug susceptibilities.Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatinLopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant womenAntimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implicationsThe epidemiological impact of HIV antiretroviral therapy on malaria in children.In vitro activity of antiretroviral drugs against Plasmodium falciparumDrugs for malaria: something old, something new, something borrowed.Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected PopulationHIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 studyEffect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort studySaquinavir inhibits the malaria parasite's chloroquine resistance transporter.Malaria and hiv in adults: when the parasite runs into the virus.Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adultsMalaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa.The effect of antiretrovirals on Plasmodium falciparum liver stagesPrevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies.Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.Unresolved antiretroviral treatment management issues in HIV-infected childrenAntiretroviral agents and prevention of malaria in HIV-infected Ugandan children.HIV treatments have malaria gametocyte killing and transmission blocking activity.Human immunodeficiency virus (HIV) and malaria interaction in sub-Saharan Africa: the collision of two Titans.Protein functional surfaces: global shape matching and local spatial alignments of ligand binding sites.Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
P2860
Q21034056-3D58A95A-3F3F-4712-8BD8-446EFAB24259Q24235145-85337C5D-D91C-4477-BDF6-641CBA7AB80AQ24538763-5410731A-90DE-4CAA-B017-676B8DA21D56Q24644157-3AEA15B2-E10B-4E0D-B476-28BFF61A14C8Q26471338-124C16EA-1F12-4300-A3C1-1631FC9A2E3EQ28475092-5842DA6C-8302-44EC-9156-02C02AA958AFQ28542863-5101BB2A-9E32-4721-B828-62DB99EDBA74Q28544968-E2A8050C-42CD-4443-9366-9B380A8CF5CCQ30373475-356E4AF4-DBB6-4FEB-A7CA-85735C611C2FQ33578923-1A4D61CA-475C-4B23-906A-F4D7183532ABQ33838319-01064EDD-160D-4B3D-8DFF-109759AB850EQ33916111-AE22A883-F8EB-4356-A4DC-14C2038A147AQ34528996-AEB459B6-38B8-47C9-AF28-EB84585D0034Q34680640-91FBAF4C-5C8E-4642-8DEE-79F9DC085A21Q34974794-1B549852-FC21-4A73-8F55-38FB3D61C526Q35004887-7AB04731-9E02-415D-948C-81E266999F01Q35012924-3C542685-651F-4EF8-AA14-E007F1D3F94EQ35286119-4175FEBF-3327-45B0-89BF-94D4BF50030EQ35347170-804870F3-25A8-4240-BB64-57D5964C97E1Q35363679-0169BE97-2075-4152-935A-494AED718BD9Q35507886-8AC5D80D-0FF8-449A-836D-28EA6E72B1D3Q35636034-CA88260F-790C-4CA8-B2E9-0345FF7CFDC8Q35656242-52CBE005-F8B6-475C-A374-4FE55FA09489Q35689395-E4AAAFF9-30AE-4A3E-B3E2-350476787B31Q35739147-F2C37006-8BBA-486E-9B8C-8EC807C87663Q35941244-C15BF14F-CEB0-472B-BAD1-507DEAF21DF6Q36033898-AD7DEF9F-ABE8-4D47-A812-0B14609A4AD4Q36144257-C7680771-AAD9-49D0-811F-35C306335542Q36218701-83A492B2-5C16-4F44-B268-5DC57ED0FF22Q36504556-78A48300-59F1-45CE-967D-A378345EFC30Q36664149-751D22FA-E332-44C6-80DC-09633091B67DQ36743880-343B8F44-9F79-4508-BA7D-771F2F00DDAFQ36744753-4E0D4DA6-FBBE-418C-B742-838564AFFA40Q36744846-6DC78B02-A9AC-4ECD-A2D9-CE179DCE0401Q36781481-6B58F9FA-218B-4752-885E-A042E44465A6Q36876420-6BEC5EF5-A634-4E6A-90F4-F144A1DD7432Q36882506-D39A0D5C-227A-4FF3-B555-745CF03A3E29Q36919663-77E137CB-4514-42C9-800C-42F35849301EQ37061605-8BD41D94-86AB-4318-8525-B4975CCB45A3Q37096787-0B43C03F-5E34-47B3-847F-DCA44F4EFC8B
P2860
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
@ast
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
@en
type
label
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
@ast
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
@en
prefLabel
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
@ast
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
@en
P2093
P2860
P1476
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
@en
P2093
Daniel E Goldberg
Eva Istvan
Sunil Parikh
P2860
P304
P356
10.1128/AAC.49.7.2983-2985.2005
P407
P577
2005-07-01T00:00:00Z